论文部分内容阅读
新辅助化疗对头颈部骨肉瘤的疗效尚存在争议。该文对1993-2013年间荷兰大于16岁的头颈部骨肉瘤患者进行回顾分析。结果:纳入研究的77例患者中,5年总生存率(OS)为55%。未接受化疗的患者,局部复发的风险明显升高。结论:新辅助化疗联合手术治疗,显著降低了局部复发的风险,值得临床推广。
The effect of neoadjuvant chemotherapy on head and neck osteosarcoma remains controversial. This paper retrospectively analyzed the patients with head and neck osteosarcoma who were over 16 years old in the Netherlands from 1993 to 2013. Results: Of the 77 patients enrolled in the study, the 5-year overall survival (OS) was 55%. In patients who have not received chemotherapy, the risk of local recurrence is significantly elevated. Conclusion: Neoadjuvant chemotherapy combined with surgical treatment significantly reduces the risk of local recurrence and deserves clinical promotion.